Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 703735, 9 pages
http://dx.doi.org/10.1155/2010/703735
Review Article

Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors

1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
2Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
3Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
4Kidney Disease Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Received 6 January 2010; Revised 16 March 2010; Accepted 14 April 2010

Academic Editor: Tianxin Yang

Copyright © 2010 Tengis S. Pavlov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Yki-Järvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. B. G. Shearer and A. N. Billin, “The next generation of PPAR drugs: do we have the tools to find them?” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1082–1093, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, no. 1, pp. 239–263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Sato, A. Sugawara, M. Kudo, A. Uruno, S. Ito, and K. Takeuchi, “Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney,” Hypertension Research, vol. 27, no. 6, pp. 417–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar · View at Scopus
  9. T. Yang, D. E. Michele, J. Park et al., “Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,” American Journal of Physiology, vol. 277, no. 6, pp. F966–F973, 1999. View at Google Scholar · View at Scopus
  10. E. Robinson and D. J. Grieve, “Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease,” Pharmacology & Therapeutics, vol. 122, no. 3, pp. 246–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Newaz, A. Blanton, P. Fidelis, and A. Oyekan, “NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)α-mediated cardiovascular effects,” Mutation Research, vol. 579, no. 1-2, pp. 163–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Guellich, T. Damy, Y. Lecarpentier et al., “Role of oxidative stress in cardiac dysfunction of PPARα/ mice,” American Journal of Physiology, vol. 293, no. 1, pp. H93–H102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Loichot, L. Jesel, A. Tesse et al., “Deletion of peroxisome proliferator-activated receptor-α induces an alteration of cardiac functions,” American Journal of Physiology, vol. 291, no. 1, pp. H161–H166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Obih and A. Oyekan, “Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice,” Blood Pressure, vol. 17, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Alonso-Galicia, B. Frohlich, and R. J. Roman, “Induction of P4504A activity improves pressure-natriuresis in Dahl S rats,” Hypertension, vol. 31, no. 1, pp. 232–236, 1998. View at Google Scholar · View at Scopus
  16. M. A. Newaz, K. Ranganna, and A. O. Oyekan, “Relationship between PPARα activation and NO on proximal tubular Na+ transport in the rat,” BMC Pharmacology, vol. 4, article 1, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. E. S. Horion, F. Whitehouse, M. N. Ghazzi, T. C. Venable, and R. W. Whitcomb, “Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group,” Diabetes Care, vol. 21, no. 9, pp. 1462–1469, 1998. View at Google Scholar · View at Scopus
  18. S. Mudaliar, A. R. Chang, and R. R. Henry, “Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications,” Endocrine Practice, vol. 9, no. 5, pp. 406–416, 2003. View at Google Scholar · View at Scopus
  19. T. Yang and S. Soodvilai, “Renal and vascular mechanisms of thiazolidinedione-induced fluid retention,” PPAR Research, Article ID 943614, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Efrati, S. Berman, E. Ilgiyeav, Z. Averbukh, and J. Weissgarten, “PPAR-γ activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats,” Nephron, vol. 106, no. 4, pp. e107–e112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Song, H. Liu, H. W. Ressom, S. Tiwari, and C. M. Ecelbarger, “Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese zucker rats as determined by microarray analysis,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 6, pp. 315–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Yousefipour, H. Hercule, L. Truong, A. Oyekan, and M. A. Newaz, “Ciglitazone, a peroxisome proliferator-activated receptor γ inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 2, pp. 461–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. Q. N. Diep, M. E. Mabrouk, J. S. Cohn et al., “Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ,” Circulation, vol. 105, no. 19, pp. 2296–2302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Sugawara, K. Takeuchi, A. Uruno et al., “Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells,” Endocrinology, vol. 142, no. 7, pp. 3125–3134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. V. T. Todorov, M. Desch, N. Schmitt-Nilson, A. Todorova, and A. Kurtz, “Peroxisome proliferator-activated receptor-γ is involved in the control of renin gene expression,” Hypertension, vol. 50, no. 5, pp. 939–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Desch, A. Schreiber, F. Schweda et al., “Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-γ in juxtaglomerular cells,” Hypertension, vol. 55, no. 3, pp. 660–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Ishizuka, O. Ito, L. Tan et al., “Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney,” Hypertension Research, vol. 26, no. 11, pp. 929–936, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Yoshioka, S. Wakino, K. Homma et al., “Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-γ ligands in ovariectomized obese rats,” Obesity, vol. 16, no. 5, pp. 965–971, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Nakagawa, V. R. Holla, Y. Wei et al., “Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1696–1702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Capdevila, J. R. Falck, and J. D. Imig, “Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension,” Kidney International, vol. 72, no. 6, pp. 683–689, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. D. Dobrian, S. D. Schriver, A. A. Khraibi, and R. L. Prewitt, “Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity,” Hypertension, vol. 43, no. 1, pp. 48–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Bishop-Bailey and T. D. Warner, “PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-γ antagonist,” The FASEBJ Journal, vol. 17, no. 13, pp. 1925–1927, 2003. View at Google Scholar
  35. R. J. Roman, “P-450 metabolites of arachidonic acid in the control of cardiovascular function,” Physiological Reviews, vol. 82, no. 1, pp. 131–185, 2002. View at Google Scholar · View at Scopus
  36. O. Ito, M. Alonso-Galicia, K. A. Hopp, and R. J. Roman, “Localization of cytochrome P-450 4A isoforms along the rat nephron,” American Journal of Physiology, vol. 274, no. 2, part 2, pp. F395–F404, 1998. View at Google Scholar · View at Scopus
  37. J. Ma, W. Qu, P. E. Scarborough et al., “Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney,” The Journal of Biological Chemistry, vol. 274, no. 25, pp. 17777–17788, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Sun, D.-H. Lin, T. Wang et al., “Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC,” American Journal of Physiology, vol. 291, no. 6, pp. F1192–F1200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Sun, W. Liu, D.-H. Lin et al., “Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 513–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Wei, D.-H. Lin, R. Kemp et al., “Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways,” Journal of General Physiology, vol. 124, no. 6, pp. 719–727, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Wei, P. Sun, Z. Wang, B. Yang, M. A. Carroll, and W.-H. Wang, “Adenosine inhibits ENaC via cytochrome P-450 epoxygenase-dependent metabolites of arachidonic acid,” American Journal of Physiology, vol. 290, no. 5, pp. F1163–F1168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Wang, Y. Wei, J. R. Falck, K. R. Atcha, and W.-H. Wang, “Arachidonic acid inhibits basolateral K channels in the cortical collecting duct via cytochrome P-450 epoxygenase-dependent metabolic pathways,” American Journal of Physiology, vol. 294, no. 6, pp. F1441–F1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Gu, Y. Wei, H. Jiang, M. Balazy, and W. Wang, “Role of 20-HETE in mediating the effect of dietary K intake on the apical K channels in the mTAL,” American Journal of Physiology, vol. 280, no. 2, pp. F223–F230, 2001. View at Google Scholar · View at Scopus
  44. W.-H. Wang, M. Lu, and S. C. Hebert, “Cytochrome P-450 metabolites mediate extracellular Ca2+-induced inhibition of apical K+ channels in the TAL,” American Journal of Physiology, vol. 271, no. 1, pp. C103–C111, 1996. View at Google Scholar · View at Scopus
  45. R.-M. Gu and W.-H. Wang, “Arachidonic acid inhibits K channels in basolateral membrane of the thick ascending limb,” American Journal of Physiology, vol. 283, no. 3, pp. F407–F414, 2002. View at Google Scholar · View at Scopus
  46. R.-M. Gu, L. Yang, Y. Zhang et al., “CYP-omega-hydroxylation-dependent metabolites of arachidonic acid inhibit the basolateral 10 pS chloride channel in the rat thick ascending limb,” Kidney International, vol. 76, no. 8, pp. 849–856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. D. G. Alvarez de la Rosa, C. M. Canessa, G. K. Fyfe, and P. Zhang, “Structure and regulation of amiloride-sensitive sodium channels,” Annual Review of Physiology, vol. 62, pp. 573–594, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Garty and L. G. Palmer, “Epithelial sodium channels: function, structure and regulation,” Physiological Reviews, vol. 77, no. 2, pp. 359–396, 1997. View at Google Scholar · View at Scopus
  49. L. Schild, “The epithelial sodium channel: from molecule to disease,” Reviews of Physiology, Biochemistry and Pharmacology, vol. 151, pp. 93–107, 2004. View at Google Scholar · View at Scopus
  50. V. Bhalla and K. R. Hallows, “Mechanisms of ENaC regulation and clinical implications,” Journal of the American Society of Nephrology, vol. 19, no. 10, pp. 1845–1854, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Song, M. A. Knepper, X. Hu, J. G. Verbalis, and C. A. Ecelbarger, “Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 426–433, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Chen, B. Yang, J. A. McNulty et al., “GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 2, pp. 718–725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. T. S. Pavlov, V. Levchenko, A. V. Karpushev, A. Vandewalle, and A. Staruschenko, “Peroxisome proliferator-activated receptor γ antagonists decrease Na+ transport via the epithelial Na+ channel,” Molecular Pharmacology, vol. 76, no. 6, pp. 1333–1340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Artunc, D. Sandulache, O. Nasir et al., “Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPAR? agonist pioglitazone,” Pflugers Archiv European Journal of Physiology, vol. 456, no. 2, pp. 425–436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. S.-Y. Chen, A. Bhargava, L. Mastroberardino et al., “Epithelial sodium channel regulated by aldosterone-induced protein sgk,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 2514–2519, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Hong, A. Lockhart, B. Davis et al., “PPAR? activation enhances cell surface ENaCa via up-regulation of SGK1 in human collecting duct cells,” The FASEBJ Journal, vol. 17, no. 13, pp. 1966–1968, 2003. View at Google Scholar
  57. C. Nofziger, L. Chen, M. A. Shane, C. D. Smith, K. K. Brown, and B. L. Blazer-Yost, “PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel,” Pflugers Archiv European Journal of Physiology, vol. 451, no. 3, pp. 445–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. V. Vallon and F. Lang, “New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure,” Current Opinion in Nephrology and Hypertension, vol. 14, no. 1, pp. 59–66, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Wilson, M. K. Mansley, J. Getty, E. M. Husband, S. K. Inglis, and M. Hansen, “Effects of peroxisome proliferator-activated receptor g agonists on Na+ transport and activity of the kinase sgk1 in epithelial cells from lung and kidney,” British Journal of Pharmacology, vol. 159, no. 3, pp. 678–688, 2010. View at Google Scholar
  61. V. Vallon, E. Hummler, T. Rieg et al., “Thiazolidinedione-induced fluid retention is independent of collecting duct αENaC activity,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 721–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. O. Khan, S. Riazi, X. Hu, J. Song, J. B. Wade, and C. A. Ecelbarger, “Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone,” American Journal of Physiology, vol. 289, no. 2, pp. F442–F450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Rubera, J. Loffing, L. G. Palmer et al., “Collecting duct-specific gene inactivation of αENaC in the mouse kidney does not impair sodium and potassium balance,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 554–565, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. A. V. Karpushev, V. Levchenko, T. S. Pavlov et al., “Regulation of ENaC expression at the cell surface by Rab11,” Biochemical and Biophysical Research Communications, vol. 377, no. 2, pp. 521–525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Staruschenko, P. Patel, Q. Tong, J. L. Medina, and J. D. Stockand, “Ras activates the epithelial Na+ channel through phosphoinositide 3-OH kinase signaling,” The Journal of Biological Chemistry, vol. 279, no. 36, pp. 37771–37778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Staruschenko, R. E. Booth, O. Pochynyuk, J. D. Stockand, and Q. Tong, “Functional reconstitution of the human epithelial Na+ channel in a mammalian expression system,” Methods in Molecular Biology, vol. 337, pp. 3–13, 2006. View at Google Scholar · View at Scopus
  67. S. Soodvilai, K. Aoyagi, and T. Yang, “PPARgamma stimulates paracellular transport and inhibits ENaC in primary inner medullary collecting duct cells,” Journal of the American Society of Nephrology, vol. 20, p. 123A, 2009. View at Google Scholar
  68. U. Panchapakesan, C. Pollock, and S. Saad, “Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake,” Nephrology, vol. 14, no. 3, pp. 298–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Saad, D. J. Agapiou, X.-M. Chen, V. Stevens, and C. A. Pollock, “The role of Sgk-1 in the upregulation of transport proteins by PPAR-γ agonists in human proximal tubule cells,” Nephrology Dialysis Transplantation, vol. 24, no. 4, pp. 1130–1141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Ollero, O. Junaidi, M. M. Zaman et al., “Decreased expression of peroxisome proliferator activated receptor ? in CFTR-/- mice,” Journal of Cellular Physiology, vol. 200, no. 2, pp. 235–244, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Nofziger, K. K. Brown, C. D. Smith et al., “PPAR? agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line,” American Journal of Physiology, vol. 297, no. 1, pp. F55–F62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Nofziger and B. L. Blazer-Yost, “PPARγ agonists, modulation of ion transporters, and fluid retention,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2481–2483, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. B. L. Blazer-Yost, “PPARγ agonists: blood pressure and edema,” PPAR Research, Article ID 785369, 2010. View at Google Scholar
  74. P. J. Bajwa, J. W. Lee, D. S. Straus, and C. Lytle, “Activation of PPARγ by rosiglitazone attenuates intestinal Cl secretion,” American Journal of Physiology, vol. 297, no. 1, pp. G82–G89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. D. P. Nichols, M. W. Konstan, and J. F. Chmiel, “Anti-inflammatory therapies for cystic fibrosis-related lung disease,” Clinical Reviews in Allergy and Immunology, vol. 35, no. 3, pp. 135–153, 2008. View at Google Scholar · View at Scopus
  76. G. S. Harmon, D. S. Dumlao, D. T. Ng et al., “Pharmacological correction of a defect in PPAR-a signaling ameliorates disease severity in Cftr-deficient mice,” Nature Medicine, vol. 16, no. 3, pp. 313–318, 2010. View at Publisher · View at Google Scholar · View at Scopus